Genotyping and antifungal susceptibility testing of Cryptococcus neoformans isolates from Cameroonian HIV-positive adult patients

Clinical Microbiology and Infection

Volumn 19, Issue 8, 2013, Pages 763-769

  Bertout, S ^a   Drakulovski, P ^a   Kouanfack, C ^b   Krasteva, D ^a   Ngouana, T ^b   Dunyach Remy C ^a   Dongtsa, J ^b   Aghokeng, A ^b   Delaporte, E ^a   Koulla Shiro, S ^b   Reynes, J ^a   Mallie M ^a  

^a INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT   (France)

^b INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT   (France)

Author keywords

AIDS; Antifungal; Cryptococcosis; Genetic diversity; Genotyping

Indexed keywords

AMPHOTERICIN B; FLUCONAZOLE; FLUCYTOSINE; FUNGAL PROTEIN; POSACONAZOLE; UNCLASSIFIED DRUG; URA5 PROTEIN; VORICONAZOLE;

AMPLIFIED FRAGMENT LENGTH POLYMORPHISM; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CAMEROON; CEREBROSPINAL FLUID; CONTROLLED STUDY; CORRELATION ANALYSIS; CRYPTOCOCCAL MENINGITIS; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; GENE AMPLIFICATION; GENETIC VARIABILITY; GENOTYPE; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IN VITRO STUDY; MIXED INFECTION; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; RESTRICTION MAPPING; SEROTYPE; SEROTYPING; SYSTEMIC THERAPY;

FILOBASIDIELLA NEOFORMANS;

EID: 84880508096     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/1469-0691.12019     Document Type: Article

References (30)

1. Bicanic T, Harrison TS. Cryptococcal meningitis Br Med Bull 2005; 72: 99-118.
2. Békondi C, Bernede C, Passone N. Primary and opportunistic pathogens associated with meningitis in adults in Bangui, Central African Republic, in relation to human immunodeficiency virus serostatus. Int J Infect Dis 2006; 10: 387-395.
3. Feng X, Yao Z, Ren D, Liao W. Simultaneous identification of molecular and mating types within the Cryptococcus species complex by PCR-RFLP analysis. J Med Microbiol 2008; 57: 1481-1490.
4. Bovers M, Hagen F, Kuramae E et al. Unique hybrids between the fungal pathogens Cryptococcus neoformans and Cryptococcus gattii. FEMS Yeast Res 2006; 6: 599-607.
5. Boekhout T, Theelen B, Diaz M et al. Hybrid genotypes in the pathogenic yeast Cryptococcus neoformans. Microbiology 2001; 147: 891-907.
6. Tay ST, Lim HC, Tajuddin TH, Rohani MY, Hamimah H, Thong KL. Determination of molecular types and genetic heterogeneity of Cryptococcus neoformans and C. gattii in Malaysia. Med Mycol 2006; 44: 617-622.
7. Mlinarić-Missoni E, Hagen F, Chew WHM, Važić-Babić V, Boekhout T, Begovac J. In vitro antifungal susceptibilities and molecular typing of sequentially isolated clinical Cryptococcus neoformans strains from Croatia. J Med Microbiol 2011; 60: 1487-1495.
8. Escandon P, Sanchez A, Martinez M, Meyer W, Castaneda E. Molecular Epidemiology Of Clinical And Environmental Isolates Of The Cryptococcus neoformans Species Complex Reveals A High Genetic Diversity And The Presence Of The Molecular Type VGII Mating Type A In Colombia. FEMS Yeast Res 2006; 6: 625-635.
9. Klaassen CH. MLST vs. Microsatellites for typing Aspergillus fumigatus isolates. Med Mycol 2009; 47: S27-S33.
10. Meyer W, Marszewska K, Amirmostofian M et al. Molecular typing of global isolates of Cryptococcus neoformans var. neoformans by polymerase chain reaction fingerprinting and randomly amplified polymorphic DNA-a pilot study to standardized techniques on which to base a detailed epidemiological survey. Electrophoresis 1999; 20: 1790-1799.
11. Meyer W, Castaneda A, Jackson S, Huynh M, Castaneda E. Molecular typing of IberoAmerican Cryptococcus neoformans isolates. Emerg Infect Dis 2003; 9: 189-195.
12. Illnait-Zaragozí MT, Martínez-Machín GF, Fernández-Andreu CM et al. Microsatellite typing and susceptibilities of serial Cryptococcus neoformans isolates from Cuban patients with recurrent cryptococcal meningitis. BMC Infect Dis 2010; 10: 289.
13. Nussbaum JC, Jackson A, Namarika D et al. Combination flucytosine and high dose fluconazole is superior to fluconazole monotherapy for cryptococcal meningitis: a randomized trial in Malawi. Clin Infect Dis 2010; 50: 338-344.
14. Clinical and Laboratory Standards Institute (CLSI). Reference method for broth dilution antifungal susceptibility testing of yeasts: third edition (M27-A3). Wayne, PA: CLSI, 2008.
15. Mdodo R, Moser SA, Jaoko W et al. Antifungal susceptibilities of Cryptococcus neoformans cerebrospinal fluid isolates from AIDS patients in Kenya. Mycoses 2011; 54: e438-e442.
16. Tewari A, Behera B, Mathur P, Xess I. Comparative Analysis of the Vitek 2 Antifungal Susceptibility System and E-test with the CLSI M27-A3 Broth Microdilution Method for Susceptibility Testing of Indian Clinical Isolates of Cryptococcus neoformans. Mycopathologia 2012; 173: 427-433.
17. Pfaller MA, Messer SA, Boyken L et al. Global trends in the antifungal susceptibility of Cryptococcus neoformans (1990-2004). J Clin Microbiol 2005; 43: 2163-2167.
18. Cogliatti M, Hallaria M, Tortorano AM, Viviani MA. Genotyping Cryptococcus neoformans var. neoformans with specific primers designed from PCR-fingerprinting bands sequenced using a modified PCR-based strategy. Med Mycol 2000; 38: 97-103.
19. Ito-Kuwa S, Nakamura K, Aoki S, Vidotto V. Serotype identification of Cryptococcus neoformans by multiplex PCR. Mycoses 2007; 50: 277-281.
20. Pfaller MA, Messer SA, Boyken L et al. In vitro activities of voriconazole, posaconazole, and fluconazole against 4169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance program. Diagn Microbiol Infect Dis 2004; 48: 201-205.
21. Chowdhary A, Randhawa HS, Sundar G et al. In vitro antifungal susceptibility profiles and genotypes of 308 clinical and environmental isolates of Cryptococcus neoformans var. grubii and Cryptococcus gattii serotype B from north-western India. J Med Microbiol 2011; 60: 961-967.
22. Lortholary O. Management of cryptococcal meningitis in AIDS: the need for specific studies in developing countries. Clin Infect Dis 2007; 45: 81-83.
23. Illnait-Zaragozi MT, Martínez FG, Curfs-Breuker I, Fernández CM, Boekhout T, Meis JF. In vitro activity of the new azole isavuconazole (BAL4815) compared with six other antifungal agents against 162 Cryptococcus neoformans isolates from Cuba. Antimicrob Agents Chemother 2008; 52: 1580-1582.
24. Adoubryn KD, Ouhon J, Cisse-Camara M et al. Etude biochimique et sérotypique de 40 souches de Cryptococcus neoformans isolées de patients VIH+ à Abidjan (Côte-d'Ivoire). J Mycol Med 2006; 16: 95-99.
25. Dromer F, Mathoulin-Pélisser S, Launay O, Lortholary O, The french cryptococcosis study group. Determinants of disease presentation and outcome during cryptococcosis : the Crypto A/D study. Plos Med 2007; 4: 297-308.
26. Feng X, Yao Z, Ren D, Liao W, Wu J. Genotype And Mating Type Analysis Of Cryptococcus neoformans And Cryptococcus gattii Isolates From China That Mainly Originated From Non-HIV-Infected Patients. FEMS Yeast Res 2008; 8: 930-938.
27. Bertout S, Renaud F, Barton R et al Genetic polymorphism of Aspergillus fumigatus in clinical samples from patients with invasive aspergillosis: investigation using four typing methods. J Clin Microbiol 2001; 39:1731-1737.
28. Nébavi F, Ayala FJ, Renaud F et al. Clonal population structure and genetic diversity of Candida albicans in AIDS patients from Abidjan (Côte d'Ivoire). Proc. Natl Acad. Sci USA 2006; 103: 3663-3668.
29. Desnos-Ollivier M, Patel S, Spaulding AR et al. Mixed infections and in vivo evolution in the human fungal pathogen Cryptococcus neoformans. mBio1: 2010; 9: 2. pii: e00091-10.
30. Trilles L, Meyer W, Wanke B, Guarro J, Lazéra M. Correlation of antifungal susceptibility and molecular type within the Cryptococcus neoformans/ C. gattii species complex. Med Mycol. 2012; 50: 328-332.